News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease



3/4/2009 10:19:41 AM

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Serentis, a privately owned biopharmaceutical company, announced today that it has started a phase II clinical trial in pruritus associated with atopic dermatitis (AD), a type of eczema. Pruritus, more commonly known as itch, is a major symptom of AD. The lack of effective treatments of pruritus has been identified as a major unmet medical need for patients with AD.

Read at BioSpace.com


comments powered by Disqus
Serentis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES